Upregulation of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases in rapid atrial pacing-induced atrial fibrillation

Allessie, 2002, Electrical, contractile and structural remodeling during atrial fibrillation, Cardiovasc. Res., 54, 230, 10.1016/S0008-6363(02)00258-4 Nattel, 2005, Mechanisms of atrial fibrillation: lessons from animal models, Prog. Cardiovasc. Dis., 48, 9, 10.1016/j.pcad.2005.06.002 Lin, 2008, Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation, Cell. Mol. Life Sci., 65, 1489, 10.1007/s00018-008-7408-8 Mukherjee, 2006, Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation, Am. J. Cardiol., 97, 532, 10.1016/j.amjcard.2005.08.073 Thijssen, 2001, Structural remodelling during chronic atrial fibrillation: act of programmed cell survival, Cardiovasc. Res., 52, 14, 10.1016/S0008-6363(01)00367-4 Singh, 2004, Role of proteases in the pathophysiology of cardiac disease, Mol. Cell. Biochem., 263, 241, 10.1023/B:MCBI.0000041865.63445.40 Mott, 2004, Regulation of matrix biology by matrix metalloproteinases, Curr. Opin. Cell Biol., 16, 558, 10.1016/j.ceb.2004.07.010 Parikka, 2005, Human mesenchymal stem cell derived osteoblasts degrade organic bone matrix in vitro by matrix metalloproteinases, Matrix Biol., 24, 438, 10.1016/j.matbio.2005.06.009 Zhang, 2005, The role and regulation of the uterine matrix metalloproteinase system in menstruating and non-menstruating species, Front. Biosci., 10, 353, 10.2741/1533 Nagase, 2006, Structure and function of matrix metalloproteinases and TIMPs, Cardiovasc. Res., 69, 562, 10.1016/j.cardiores.2005.12.002 Page-McCaw, 2007, Matrix metalloproteinases and the regulation of tissue remodelling, Nat. Rev. Mol. Cell Biol., 8, 221, 10.1038/nrm2125 Creemers, 2001, Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?, Circ. Res., 89, 201, 10.1161/hh1501.094396 Spinale, 2002, Matrix metalloproteinases: regulation and dysregulation in the failing heart, Circ. Res., 90, 520, 10.1161/01.RES.0000013290.12884.A3 Newby, 2005, Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture, Physiol. Rev., 85, 1, 10.1152/physrev.00048.2003 Coker, 1999, Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations, Am. J. Physiol., 277, H777 Mukherjee, 2006, Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction, Am. J. Physiol.: Heart Circ. Physiol., 291, H2216 Gomez, 1997, Tissue inhibitors of metalloproteinases: structure, regulation and biological functions, Eur. J. Cell Biol., 74, 111 Chen, 2007, Altered expression of FHL1, CARP, TSC-22 and P311 provide insights into complex transcriptional regulation in pacing-induced atrial fibrillation, Biochim. Biophys. Acta, 1772, 317, 10.1016/j.bbadis.2006.10.017 Lin, 2007, Increased expression of extracellular matrix proteins in rapid atrial pacing-induced atrial fibrillation, Heart Rhythm, 4, 938, 10.1016/j.hrthm.2007.03.034 Pan, 2007, Downregulation of angiotensin converting enzyme II is associated with pacing-induced sustained atrial fibrillation, FEBS Lett., 581, 526, 10.1016/j.febslet.2007.01.014 Lin, 2003, Electrophysiological mapping and histological examinations of the swine atrium with sustained (> or = 24 h) atrial fibrillation: a suitable animal model for studying human atrial fibrillation, Cardiology, 99, 78, 10.1159/000069728 Yan, 2003, In situ zymography: a molecular pathology technique to localize endogenous protease activity in tissue sections, Vet. Pathol., 40, 227, 10.1354/vp.40-3-227 Turini, 1969, The action of phenylmethylsulfonyl fluoride on human acetylcholinesterase, chymotyrpsin and trypsin, J. Pharmacol. Exp. Ther., 167, 98 Stawowy, 2004, Regulation of matrix metalloproteinase MT1-MMP/MMP-2 in cardiac fibroblasts by TGF-beta1 involves furin-convertase, Cardiovasc. Res., 63, 87, 10.1016/j.cardiores.2004.03.010 Stetler-Stevenson, 1989, The activation of human type IV collagenase proenzyme. Sequence identification of the major conversion product following organomercurial activation, J. Biol. Chem., 264, 1353, 10.1016/S0021-9258(18)94193-1 Oliver, 1997, Quantitative reverse zymography: analysis of picogram amounts of metalloproteinase inhibitors using gelatinase A and B reverse zymograms, Anal. Biochem., 244, 161, 10.1006/abio.1996.9895 Goldberg, 1992, Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin, J. Biol. Chem., 267, 4583, 10.1016/S0021-9258(18)42873-6 Kjeldsen, 1993, Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase, J. Biol. Chem., 268, 10425, 10.1016/S0021-9258(18)82217-7 Olson, 2000, Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1, J. Biol. Chem., 275, 2661, 10.1074/jbc.275.4.2661 Hoit, 2002, Remodeling of the left atrium in pacing-induced atrial cardiomyopathy, Mol. Cell. Biochem., 238, 145, 10.1023/A:1019988024077 Nakano, 2004, Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation, J. Am. Coll. Cardiol., 43, 818, 10.1016/j.jacc.2003.08.060 Xu, 2004, Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation, Circulation, 109, 363, 10.1161/01.CIR.0000109495.02213.52 Peterson, 2000, Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat, Cardiovasc. Res., 46, 307, 10.1016/S0008-6363(00)00029-8 Boixel, 2003, Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat, J. Am. Coll. Cardiol., 42, 336, 10.1016/S0735-1097(03)00578-3 Meiners, 2004, Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome, Hypertension, 44, 471, 10.1161/01.HYP.0000142772.71367.65 Maquart, 1988, Stimulation of collagen synthesis in fibroblast cultures by the tripeptide–copper complex glycyl-l-histidyl-l-lysine-Cu2+, FEBS Lett., 238, 343, 10.1016/0014-5793(88)80509-X Wegrowski, 1992, Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide–copper complex glycyl-l-histidyl-l-lysine-Cu2+, Life Sci., 51, 1049, 10.1016/0024-3205(92)90504-I Engsig, 2000, Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones, J. Cell. Biol., 151, 879, 10.1083/jcb.151.4.879 Yu, 2000, Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis, Genes Dev., 14, 163, 10.1101/gad.14.2.163 Nagase, 1999, Matrix metalloproteinases, J. Biol. Chem., 274, 21491, 10.1074/jbc.274.31.21491 Murphy, 1999, Mechanisms for pro matrix metalloproteinase activation, APMIS, 107, 38, 10.1111/j.1699-0463.1999.tb01524.x Bannikov, 2002, Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide, J. Biol. Chem., 277, 16022, 10.1074/jbc.M110931200 Ogata, 1995, Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases, J. Biol. Chem., 270, 18506, 10.1074/jbc.270.31.18506 Olson, 1998, High affinity binding of latent matrix metalloproteinase-9 to the alpha2(IV) chain of collagen IV, J. Biol. Chem., 273, 10672, 10.1074/jbc.273.17.10672 Caterina, 1998, Glycosylation and NH2-terminal domain mutants of the tissue inhibitor of metalloproteinases-1 (TIMP-1), Biochim. Biophys. Acta, 1388, 21, 10.1016/S0167-4838(98)00158-7 Goldberg, 1992, Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin, J. Biol. Chem., 267, 4583, 10.1016/S0021-9258(18)42873-6 Han, 2002, Tumor necrosis factor-alpha-induced proteolytic activation of pro-matrix metalloproteinase-9 by human skin is controlled by down-regulating tissue inhibitor of metalloproteinase-1 and mediated by tissue-associated chymotrypsin-like proteinase, J. Biol. Chem., 277, 27319, 10.1074/jbc.M202842200 Kim, 2008, Functional proteomics study reveals that N-acetylglucosaminyltransferase V reinforces the invasive/metastatic potential of colon cancer through aberrant glycosylation on tissue inhibitor of metalloproteinase, Mol. Cell. Proteomics, 7, 1, 10.1074/mcp.M700084-MCP200 Butler, 1999, Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B. Regulation by polyanions, J. Biol. Chem., 274, 10846, 10.1074/jbc.274.16.10846 Hayakawa, 1994, Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2), J. Cell. Sci., 107, 2373, 10.1242/jcs.107.9.2373 Kolkenbrock, 1991, The complex between a tissue inhibitor of metalloproteinases (TIMP-2) and 72-kDa progelatinase is a metalloproteinase inhibitor, Eur. J. Biochem., 198, 775, 10.1111/j.1432-1033.1991.tb16080.x